Method for performing treatment determination of prostatic cancer

18F-DCFPyL PET/CT imaging addresses the challenge of accurately detecting prostate cancer metastases by targeting PSMA, enhancing diagnostic accuracy and treatment management for prostate cancer patients.

JP2024161375AInactive Publication Date: 2024-11-19PROGENICS PHARMACEUTICALS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024114470
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-05-02
Filing Date
2024-07-18
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for diagnosing and managing prostate cancer, particularly metastatic or recurrent prostate cancer, lack the sensitivity and specificity needed to accurately detect and manage pelvic and distant metastases, leading to inadequate treatment decisions.

Method used

The use of 18F-DCFPyL PET/CT imaging, which targets prostate-specific membrane antigen (PSMA), allows for the visualization of metastases, particularly those larger than 4 mm, providing high sensitivity and positive predictive value in detecting pelvic lymph node metastases and other distant metastases.

Benefits of technology

18F-DCFPyL PET/CT imaging demonstrates high sensitivity and specificity in detecting pelvic lymph node metastases and distant metastases, enabling more informed treatment decisions and management strategies for prostate cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161375000006
    Figure 2024161375000006
  • Figure 2024161375000007
    Figure 2024161375000007
  • Figure 2024161375000001
    Figure 2024161375000001
Patent Text Reader

Abstract

To provide a method for performing treatment or treatment management determination of prostatic cancer.SOLUTION: A method includes: determining presence of one or more metastasis in a subject on 18F-DCFPyL PET / CT; and treating the subject or performing treatment management determination regarding the subject on the basis of the presence of one or more metastasis, where the subject has metastatic or recurrent prostatic cancer, or is suspicious to have metastatic or recurrent prostatic cancer.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit of priority under 35 U.S.C. §119 to U.S. Provisional Application No. 62 / 744,400, filed October 11, 2018, U.S. Provisional Application No. 62 / 754,520, filed November 1, 2018, U.S. Provisional Application No. 62 / 804,081, filed February 11, 2019, and U.S. Provisional Application No. 62 / 842,136, filed May 2, 2019, the entire contents of each of which are incorporated by reference herein. [Background technology]

[0002] 2. Background of the Invention Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated 1 in 7 men will be diagnosed with prostate cancer in their lifetime. The American Cancer Society estimates that approximately 164,609 new cases of prostate cancer will be diagnosed each year, and approximately 26,730 men will die from the disease. Approximately 2,900,000 men in the United States are now added to the list of prostate cancer survivors. New methods are needed to expand treatment and treatment management options. Summary of the Invention

[0003]

[0023] In one aspect, a method of treating or making treatment management decisions regarding prostate cancer in a subject, comprising: 18The method includes determining the presence or absence of one or more metastases in the subject by F-DCFPyL PET / CT. In one embodiment of such method, the method further includes treating the subject or making a treatment management decision for the subject based on the presence or absence of one or more metastases. In one embodiment of any one of the methods provided herein, the determining is based on obtaining or being given a result of any one of the methods of assessment provided herein. In one embodiment of any one of the methods provided herein, the determining is based on performing any one of the methods of assessment provided herein.

[0004] In one embodiment of any one of the methods provided herein, the subject is any one of the subjects defined herein, such as having metastatic or recurrent prostate cancer or suspected of having metastatic or recurrent prostate cancer. In one embodiment of any one of the methods provided herein, the subject has an extraprostatic disease or is suspected of having metastatic or extraprostatic disease. In one embodiment of any one of the methods provided herein, the subject has a pelvic (e.g., lymph node) metastasis or is suspected of having a pelvic (e.g., lymph node) metastasis. In one embodiment of any one of the methods provided herein, the subject has a distant metastasis or is suspected of having a distant metastasis. In one embodiment of any one of the methods provided herein, the subject has nodal, bone, and / or visceral / soft tissue metastasis.

[0005] In one embodiment of any one of the methods provided herein, one or more of the metastases is greater than 4 mm. In one embodiment of any one of the methods provided herein, the median lymph node metastasis is >4 mm. In one embodiment of any one of the methods provided herein, 18 F-DCFPyL is administered to subjects 1 to 2 hours prior to PET / CT. In one embodiment of any one of the methods provided herein, 9 mCi (333 MBq) 18 F-DCFPyL is administered to subjects via IV injection.

[0006] In one embodiment of any one of the methods provided herein, the method further comprises treating the subject based on said determination. In one embodiment of any one of the methods provided herein, the treatment is any one of the treatments provided herein. In one embodiment of any one of the methods provided herein, the method further comprises making a treatment management decision. In one embodiment of any one of the methods provided herein, making a treatment management decision includes any one or more of the treatment management decisions provided herein.

[0007] In one embodiment of any one of the methods provided herein, the subject has undergone a prior diagnostic test, such as a PSA test or a conventional imaging test.In one embodiment of any one of the methods provided herein, the prior diagnostic test is a negative or equivocal finding for prostate cancer in a conventional imaging test.

[0008] In one embodiment of any one of the methods provided herein, the method further comprises carrying out additional diagnostic test for the subject, such as PSA test or conventional imaging test.In one embodiment of any one of the methods provided herein, the PSA test result is detectable or rising PSA in the subject after radical prostatectomy.In one embodiment of any one of the methods provided herein, the PSA test result is the increase in PSA level in the subject after radiation therapy, cryotherapy or brachytherapy. [Brief description of the drawings]

[0009] [Figure 1] FIG. 1 shows the OSPREY study design and cohort. [Diagram 2] Figure 2 shows the diagnostic performance in pelvic lymph nodes. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] Detailed Description of the Invention Also referred to herein as PyL 18 F-DCFPyL is a fluorinated PSMA-targeted positron emission tomography / computed tomography ("PET / CT") imaging agent that allows visualization of metastases, such as bone and soft tissue metastases. Surprisingly, it has been found that imaging with such agents can be used to determine the presence or absence of recurrent or metastatic prostate cancer with high levels of sensitivity or positive predictive value for subjects as defined herein.

[0011] The subject as defined herein is one who has or is suspected to have metastatic or recurrent prostate cancer that expresses PSMA.PSMA is a 100kd type II membrane glycoprotein that is expressed in prostate tissue (Horoszewicz et al., 1987, Anticancer Res. 7:927-935; U.S. Patent No. 5,162,504).PSMA has been characterized as a type II transmembrane protein with sequence homology to transferrin receptor (Israeli et al., 1994, Cancer Res. 54:1807-1811) and with NAALADase activity (Carter et al., 1996, Proc. Natl. Acad. Sci. USA 93:749-753). PSMA is expressed in increased amounts in prostate cancer (Horoszewicz et al., 1987, Anticancer Res. 7:927-935; Rochon et al., 1994, Prostate 25:219-223; Murphy et al., 1995, Prostate 26:164-168; and Murphy et al., 1995, Anticancer Res. 15:1473-1479).

[0012] It was also surprisingly found that in some embodiments, the identification of pelvic lymph node metastases larger than 4 mm provided even greater predictive power and sensitivity. Thus, in any one of the methods provided herein, the subject has (or is suspected of having) a metastasis, such as a pelvic lymph node metastasis larger than 4 mm.

[0013] "Metastatic" as used herein refers to cancer that has spread from primary cancer or primary cancer site. In prostate cancer, metastasis can be outside the prostate. Metastasis can occur within the pelvis, such as in pelvic lymph nodes, or can be at a site distant from the pelvis (also referred to herein as "distant metastasis"). In one embodiment of any one of the methods provided herein, metastasis is pelvic lymph node metastasis or metastasis at other distant sites. "Recurrent" as used herein refers to prostate cancer that occurs after an initial prostate cancer event or that has survived treatment.

[0014] In one aspect, there is provided a method of treating or making a treatment management decision for any one of the subjects defined herein, comprising: 18 The methods include identifying metastases in a subject with F-DCFPyL PET / CT imaging, and treating the subject or making a treatment management decision for the subject based on the presence or absence of identified metastases.

[0015] "Treatment" as used herein refers to any clinical activity that is taken or recommended to be taken to reduce or eliminate prostate cancer in a subject, or to provide some benefit to a subject, such as reducing symptoms as a result of having prostate cancer.Prostate cancer treatment includes, but is not limited to, surgery, radiation, cryotherapy, brachytherapy, chemotherapy, or hormone / androgen deprivation therapy (ADT) treatment.In any one of the methods provided herein, treating or treating a subject can include providing any one of the forms of treatment provided herein, or recommending providing such treatment to the subject.

[0016] In one embodiment of any one of the methods provided herein, the treating or treatment of the subject comprises I-131 1095 in combination with enzalutamide. I-131 (iodine-131) 1095, a small molecule therapeutic, binds to the extracellular domain of PSMA. Preclinical data showed high tumor uptake and good tumor-to-kidney discrimination, producing a lethal dose to the tumor while minimizing normal tissue dose. In a human prostate cancer mouse model, the compound administered in a single or multiple dose schedule significantly reduced tumor burden over time and enhanced survival without significant signs of toxicity. When used in a sensitive use setting, I-131 1095 significantly reduced PSA levels and bone pain, but was well tolerated in a group of heavily pretreated advanced prostate cancer patients.

[0017] The chemical structure of I-131 1095 (or 131I 1095) (i.e., 131I-(S)-2-(3((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid) is: [ka] It is.

[0018] Enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof are also included in the definition of "I-131 1095". U.S. Patent No. 8,487,129 describes such compounds, and these compounds and methods for making them are incorporated herein by reference. In one embodiment, these compounds are for use in any one of the methods and compositions provided herein.

[0019] "Making a treatment management decision," as used herein, refers to any decision that a clinician may make about a subject with prostate cancer in order to monitor and / or treat prostate cancer in the subject. Treatment management decisions include, but are not limited to, deciding to perform a biopsy, changing the location at which a biopsy is performed, changing the frequency at which a biopsy is performed, deciding to perform surgery, changing the type of surgery to perform, changing the location at which surgery is performed, changing the timing at which surgery is performed, deciding to administer radiation, changing the type of radiation to administer, deciding the dose of radiation to administer, deciding the location at which radiation is administered, changing the dose of radiation to administer, changing the location at which radiation is administered, deciding to perform chemotherapy, changing the type of chemotherapy to administer, deciding the dose of chemotherapy to administer, changing the dose of chemotherapy to administer, changing the regimen for administering chemotherapy, deciding to administer hormone / ADT therapy, changing the type of hormone / ADT therapy to administer, deciding the dose of hormone / ADT therapy to administer, changing the dose of hormone / ADT therapy to administer, and changing the regimen for administering hormone / ADT therapy.

[0020] In any one of the methods provided herein, making a treatment management decision can include one or more of the foregoing. In any one of the methods provided herein, the method can further include treating or monitoring the subject (or recommending that the subject be treated or monitored) according to the treatment management decision.

[0021] The subject of any one of the methods provided herein can have (or be suspected of having) metastatic or recurrent prostate cancer. In some embodiments of any one of the methods provided, the subject may have high or elevated prostate specific antigen (PSA) levels, such as with elevated PSA of 0.2ng / mL or more above nadir.In some embodiments of such subjects, the subject has undergone radiation therapy, cryotherapy, or brachytherapy.In some embodiments of any one of the methods provided herein, the subject has undergone radiation therapy, cryotherapy, or brachytherapy, or the method comprises treating the subject with radiation therapy, cryotherapy, or brachytherapy.

[0022] In some embodiments of any one of the methods provided, the subject can have high or elevated prostate specific antigen (PSA) levels, such as detectable or elevated PSA above 0.2ng / mL or more above nadir and confirmatory PSA above 0.2ng / mL.In some embodiments of such subjects, the subject can have undergone radical prostatectomy.In some embodiments of any one of the methods provided herein, the subject has undergone radical prostatectomy or the method comprises treating the subject with radical prostatectomy.

[0023] In some embodiments of any one of the methods provided herein, the subject may have a negative or equivocal finding for prostate cancer by conventional imaging test, such as conventional imaging test performed as part of standard treatment workup.Conventional imaging methods include, but are not limited to, pelvic CT / MRI, whole body scan, NaF, fluciclovine or choline PET.In some embodiments of any one of the methods provided herein, the subject has undergone or the method includes the step of assessing the subject with conventional imaging. In some embodiments of any one of the methods provided herein, the subject has undergone a PSA level test or the method includes a step of testing PSA levels in the subject.

[0024] In one embodiment of any one of the methods provided herein, the subject has had a prior anti-androgen treatment, such as with abiraterone. In another embodiment of any one of the methods provided herein, such subject has had a prior anti-androgen treatment, such as with abiraterone, but has not had a prior cytotoxic chemotherapy, such as with taxane chemotherapy. In another embodiment of any one of the methods provided herein, such subject has prostate cancer that has progressed despite these prior treatment(s). In another embodiment of any one of the methods provided herein, such subject has mCRPC that has progressed despite these prior treatment(s).

[0025] In one embodiment of any one of the methods provided herein, the subject has undergone multiple rounds of prior anti-androgen therapy, such as with abiraterone. In another embodiment of any one of the methods provided herein, the subject has undergone prior anti-androgen therapy, such as with abiraterone, but has not undergone prior cytotoxic chemotherapy, such as with taxane chemotherapy. In another embodiment of any one of the methods provided herein, any one of such subjects has prostate cancer that has progressed despite these prior treatment(s). In another embodiment of any one of the methods provided herein, any one of such subjects has mCRPC that has progressed despite these prior treatment(s).

[0026] "Antiandrogens" as used herein refers to agents that block (e.g., inhibit) the action of androgen hormones and androgen-regulating molecules. Adrenergic receptor antagonists are considered to be antiandrogens herein. The term "antiandrogens" encompasses antiandrogens, antiandrogen analogs, and antiandrogen derivatives. In prostate cancer, antiandrogens block the activity of testosterone, which typically slows the growth of prostate cancer. In some embodiments, antiandrogens block the enzyme cytochrome P450 17A1, which is encoded by the CYP17A gene. Antiandrogens may be steroidal or nonsteroidal (also referred to as "pure"). Examples of antiandrogens include, but are not limited to, abiraterone (ZYTIGA®), enzalutamide (XTANDI®), nilutamide (NILANDRON®), flutamide (EULEXIN®), bicalutamide (CASODEX®), and orteronel (TAK-700, Tokai Pharmaceuticals, Inc.).

[0027] "Progression" as used herein refers to the cell proliferation of prostate cancer that has not been reduced by any one of the preceding treatments or combinations thereof mentioned herein.Disease progression can be indicated by rising PSA levels (e.g., an increase of ≧25% from baseline or preceding measurement and ≧2ng / ml of nadir, with or without a second such assessment of progression after ≧3 weeks), soft tissue disease progression as defined by RECIST1.1, bone disease progression as defined by two or more new lesions on bone scan, and / or new pain in the area of ​​radiographically evident disease.In one embodiment of any one of the methods provided herein, the progressing prostate cancer is not substantially inhibited by those preceding treatments or combinations and is considered non-responsive by the clinician.

[0028] In one embodiment of any one of the methods provided herein, the subject has or has had soft tissue or bone progression, such as by a scan showing progression relative to a comparative scan performed during prior abiraterone therapy or after discontinuation from abiraterone. In one embodiment of any one of the methods provided herein, the subject has or has had soft tissue or bone progression, such as by a scan showing progression relative to the results of a previous scan performed during prior abiraterone therapy or after discontinuation from abiraterone.

[0029] example Example 1 - In a patient with prostate cancer 18 A Prospective Phase 2 / 3 Multi-Center Study of F-DCFPyL PET / CT Imaging: Examination of Diagnostic Accuracy 18 F-DCFPyL PET / CT Imaging in Patients with PRostate Cancer - Examination of Diagnostic AccuracY)(OSPREY) background Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed by prostate cancer (PCa) cells and a novel PET radiotracer. 18 An example of this is the use of F-DCFPyL to detect pelvic lymph node metastases and other distant disease sites in men with PCa. 18 Our aim was to determine the diagnostic performance of F-DCFPyL PET / CT.

[0030] method In 385 men with high-risk PCa scheduled for radical prostatectomy and lymphadenectomy (Cohort A, n=268) or with radiological evidence of metastatic PCa amenable to biopsy (Cohort B, n=117); 18F-DCFPyL PET / CT was evaluated. 18 F-DCFPyL was administered 1 to 2 hours before PET / CT. 18 Coprimary endpoints of sensitivity and specificity of F-DCFPyL PET / CT were evaluated in cohort A. Secondary endpoints included safety in both cohorts, positive predictive value (PPV) and negative predictive value (NPV) in cohort A, and sensitivity and PPV in cohort B. Three central, blinded, and independent readers 18 F-DCFPyL scans were evaluated. Histopathology served as the reference standard against which imaging findings were compared. Figure 1 provides information regarding the study design and cohort.

[0031] result In cohort A (n=252 evaluable), 18 The sensitivity of F-DCFPyL PET / CT ranged from 30.6 to 41.9% (lower limit of 95% CI: 19.2 to 29.7%) among the three readers, with a range of specificities from 96.3 to 98.9% (lower limit of 95% CI: 93.6 to 96.0%). In addition, the PPV and NPV ranged from 78.1 to 90.5% and 81.4 to 83.8%, respectively. When restricting the analysis to median nodal metastases >4 mm, there was a marked improvement in sensitivity (ranged from 51.7 to 65.5%; lower limit of 95% CI: 33.5 to 48.0%). In patients with distant metastatic PCa (cohort B, n=93 evaluable), sensitivity and PPV values ​​ranged from 92.9 to 98.6% (lower limit of 95% CI: 84.0 to 91.6%) and 81.2 to 87.8%, respectively. No drug-related serious adverse events were observed, and 27 (7.0%) men experienced ≥1 drug-related adverse event, with dysgeusia (2.1%) and headache (2.1%) being the most common.

[0032] Diagnostic Performance Overview (Evaluable Set) Pelvic lymph node diagnosis overview The first coprimary endpoint, specificity, ranged from 96% to 99% and was statistically significant at the prespecified limit of 80%. The second coprimary endpoint, sensitivity, ranged from 31 to 42% and did not meet the prespecified confidence limit of 40%. High PPV (78-91%) and NPV (81-84%) performance 18 Demonstrating the strong clinical utility of F-DCFPyL PET / CT, providing physicians with the confidence to trust the test results Overview of metastasis diagnosis A secondary efficacy endpoint representing recurrent or metastatic disease outside the pelvis (e.g., bone, soft tissue, and lymph nodes) In this patient population, the high sensitivity (93–99%) and PPV (81–88%) provide strong clinical utility for accurately detecting distant metastatic disease.

[0033] Overview of Extraprostate Diagnostics Detect extraprostatic disease, including pelvic lymph nodes from extended pelvic lymphadenectomy and distant metastases or recurrent disease from targeted biopsy 18 The performance of F-DCFPyL was statistically significant across all diagnostic parameters. This pooled analysis improves the overall sensitivity of PyL to detect metastatic disease (both pelvic and distant). Cohorts A and B Prostate Overview This is a preliminary endpoint demonstrating that PyL detects prostate cancer with near perfect sensitivity and PPV Confirm that these are high-risk prostate cancer patients

[0034] A change in the medical management of a subject's care (e.g., defined as a change in one or more of the following): Table 1 [Table 1]

[0035] Changes in management based on serial review of centrally read pre-PyL imaging and clinical characteristics followed by re-review of PyL imaging results In one instance, changes in management appeared to be indicated in ~43% of subjects after review of PyL PET / CT images, with the largest changes to planned hormonal therapy. Cohort A

[0036] conclusion 18 F-DCFPyL PET / CT was well tolerated and demonstrated high overall diagnostic performance in detecting pelvic lymph node metastases and other distant sites of metastatic disease, as supported by its high specificity and PPV. These data suggest that it may enable more accurately informed treatment choices in men with prostate cancer.

[0037] Example 2 - In a patient with suspected recurrence of prostate cancer 18 F-DCFPyL PET / CT Imaging Study (CONDOR) Table 2 [Table 2]

[0038] Measure results Main outcome measures: 1. 18 Correct Localization Rate (CLR), defined as the percentage of subjects with a one-to-one correspondence between at least one lesion identified on F-DCFPyL PET / CT imaging and a composite truth standard defined as either evaluable histopathology, informative correlative imaging, or PSA response after radiotherapy. Within 60 days following PyL PET / CT imaging, either biopsy / surgery, conventional imaging, or locoregional radiation therapy of the suspected PyL lesion(s) will be performed.

[0039] Secondary outcome measures: 2. Intended prostate cancer treatment plan 18 Percentage of subjects with changes attributable to F-DCFPyL PET / CT imaging results. Changes in intended prostate cancer treatment plans were based on Medical Management Questionnaires completed before and after PyL PET / CT imaging.

[0040] Eligibility Minimum age: 18 years old Maximum age: Gender: Male Based on Gender: Yes - only male subjects will be enrolled in this study. Accepting healthy volunteers: No Criteria: Recruitment Criteria: Male > / = 18 years old Histopathologically confirmed prostate cancer with subsequent definitive treatment for the original diagnosis Suspected recurrence of prostate cancer based on a rising PSA after definitive treatment based on: a. Post-radical prostatectomy: detectable or rising PSA ≥ 0.2 ng / mL with confirmatory PSA ≥ 0.2 ng / mL (American Urological Association [AUA]); or b. Post-radiotherapy, cryotherapy, or brachytherapy: Increased PSA level above nadir ≥ 2 ng / mL (American Society for Radiation Therapy oncology [ASTRO]-Phoenix) Negative or equivocal findings for prostate cancer on conventional imaging studies performed as part of a standard of care workup within 60 days prior to Day 1 Conventional imaging findings per institutional standard of care (SOC scan(s) (e.g., pelvic CT / MRI, total body bone scan, NaF, fluciclovine, or choline PET) completed less than 60 days prior to Day 1. SOC scan(s) performed more than 60 days prior to Day 1 may be repeated as a study screening procedure and reviewed by the examining physician prior to Day 1. Life expectancy ≥ 6 months as determined by the examining physician Ability and willingness to provide informed consent and comply with protocol requirements

[0041] Exclusion criteria: Subjects who have received any high-energy (>300 KeV) gamma-ray emitting radioisotope within 5 physical half-lives prior to Day 1 Ongoing treatment with any systemic therapy for prostate cancer (e.g., ADT, antiandrogens, GnRH, LHRH agonists or antagonists) Treatment with ADT in the past 3 months on day 1 Have received investigational treatment for prostate cancer within 60 days prior to Day 1 Subjects who, in the opinion of the Investigating Physician, have any medical condition or other circumstances which compromise the subject's safety or compliance in generating reliable data or completing the study.

[0042] Example 3 - Results from the OSPREY trial: In patients with prostate cancer 18 A prospective phase 2 / 3 multicenter study of F-DCFPyL PET / CT imaging - Examining diagnostic accuracy background Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed by prostate cancer (PCa) cells. PSMA-based imaging is considered to be highly promising for PCa detection and is a novel PET radiotracer. 18This prospective, multicenter trial is evaluating the efficacy and safety of F-DCFPyL in detecting pelvic lymph node metastases and sites of distant metastases in men with PCa. 18 This study was designed to determine the safety and diagnostic performance of F-DCFPyL PET / CT.

[0043] method In 385 men with high-risk PCa who were scheduled for radical prostatectomy with lymphadenectomy (Cohort A) or who were scheduled for biopsy and had radiological evidence of recurrent or metastatic PCa (Cohort B), 18 F-DCFPyL PET / CT was evaluated. 18 F-DCFPyL was administered 1-2 hours before PET / CT. 18 The coprimary endpoints of sensitivity and specificity of F-DCFPyL PET / CT were evaluated in cohort A. Key secondary endpoints were incidence of adverse events, efficacy and safety of F-DCFPyL PET / CT for detecting pelvic lymph node metastases in cohort A. 18 Positive predictive value (PPV) and negative predictive value (NPV) of F-DCFPyL PET / CT imaging for detecting prostate cancer within sites of metastasis or recurrence in cohort B 18 The sensitivity and PPV of F-DCFPyL PET / CT imaging were assessed by 3 central, blinded, and independent readers. 18 F-DCFPyL scans were evaluated and imaging findings were compared with histopathology as the reference standard.

[0044] result For detection of pelvic lymph node metastases in cohort A (n=252 evaluable), 18F-DCFPyL PET / CT imaging had a median sensitivity of 40.3% (95% CI: 28.1-52.5%), a median specificity of 97.9% (95% CI: 94.5-99.4%), and a median PPV and NPV of 86.7% (95% CI: 69.7-95.0%) and 83.2% (95% CI: 78.0-88.0%), respectively. In cohort B (n=93 evaluable), the median sensitivity and PPV were 95.8% (95% CI: 87.8-99.0%) and 81.9% (95% CI: 73.7-90.2%), respectively. 18 The sensitivity and PPV of F-DCFPyL PET / CT were evaluated in cohort B in different lesion locations on regional levels (prostate, pelvis, and extrapelvic). The median sensitivity and PPV for the pelvic region were 100% (95%CI: N / A) and 79.5% (95%CI: 67.0-92.0%), respectively; and the median sensitivity and PPV for the extrapelvic region were 94.9% (95%CI: 82.0-99.0%) and 86.1% (95%CI: 76.0-96.0%), respectively. No evaluable subjects had local recurrence in the prostate region for analysis. Individual reader assessments are shown in the table below. No drug-related serious adverse events were observed. Twenty-seven (7.0%) men experienced ≥1 drug-related adverse event, with dysgeusia (2.1%) and headache (2.1%) being the most common.

[0045] conclusion 18 F-DCFPyL PET / CT had a favorable toxicity profile and was generally well tolerated in patients with PCa. 18 F-DCFPyL PET / CT demonstrated high sensitivity in reliably detecting distant metastatic prostate cancer and high specificity in confirming the absence of pelvic lymph node metastasis. 18 The associated strong PPV and NPV of F-DCFPyL imaging suggest its potentially high clinical utility. 18F-DCFPyL is currently under investigation in a phase 3 trial in patients with biochemical recurrence of PCa.

[0046] Table 3. Diagnostic performance by area (Cohort B) [Table 3]

[0047] Example 4 - OSPREY trial 18 Diagnostic performance of F-DCFPyL in patients (Pts) with known or suspected metastatic prostate cancer (mPC) 18 A prospective phase 2 / 3 multicenter study of F-DCFPyL PET / CT imaging background Accurate detection of prostate cancer is essential for patient management, yet standard imaging methods still perform poorly in accurately detecting mPC. 18 F-DCFPyL is a novel PET imaging agent that selectively binds to prostate-specific membrane antigen, a recognized target for prostate cancer. OSPREY was a prospective, multicenter study in patients with either newly diagnosed high-risk prostate cancer (Cohort A) or known or suspected mPC (Cohort B). Here we focus on Cohort B.

[0048] method 117 men scheduled for biopsy for recurrent or mPC 18 F-DCFPyL. The patient underwent image-guided biopsy. 18 Sensitivity, positive predictive value (PPV), and safety of F-DCFPyL PET / CT were the primary endpoints for Cohort B. 18 F-DCFPyL PET / CT scans were evaluated by 3 independent, blinded central readers; and results were compared with histopathology as the truth standard.

[0049] result When compared with histopathology 18 The sensitivity and PPV of F-DCFPyL PET / CT ranged from 92.9 to 98.6% (lower limit of 95% CI: 84.0 to 91.6%) and 81.2 to 87.8%, respectively. Diagnostic performance by anatomic location showed high sensitivity and high PPV in all disease sites (see table below). Only 2 (1.7%) Cohort B patients experienced ≥ 1 drug-related AE (dysgeusia and generalized rash), both of which were mild in severity (grade 1).

[0050] conclusion 18 F-DCFPyL PET / CT was well tolerated and demonstrated high sensitivity and PPV in accurately detecting nodal, bone, and / or visceral / soft tissue metastases. 18 F-DCFPyL PET / CT scans are more likely to reveal pathologically proven distant disease, which may be of value as a PET imaging agent with a positive impact on treatment planning. 18 Demonstrate the potential of F-DCFPyL.

[0051] Table 4 [Table 4]

Claims

1. 1. A method of treating or managing the treatment of prostate cancer in a subject, comprising: 18 Determining the presence or absence of one or more metastases in the subject by F-DCFPyL PET / CT; and Treating a subject or making a treatment management decision about a subject based on the presence or absence of one or more metastases Including, The method, wherein the subject has metastatic or recurrent prostate cancer or is suspected of having metastatic or recurrent prostate cancer.

2. 10. The method of claim 1, wherein the subject has an extraprostatic lesion or is suspected of having a metastatic or extraprostatic lesion.

3. The method of claim 1 or 2, wherein the subject has or is suspected of having a pelvic metastasis.

4. The method of any one of claims 1 to 3, wherein the subject has or is suspected of having distant metastasis.

5. The method of any one of claims 1 to 4, wherein the subject has nodal, bony and / or visceral / soft tissue metastases.

6. The method of any one of claims 1 to 5, wherein one or more of the metastases are greater than 4 mm.

7. 7. The method of claim 6, wherein the mean or median lymph node metastasis is >4 mm.

8. 18 The method of any one of claims 1 to 7, wherein F-DCFPyL is administered to the subject 1 to 2 hours prior to PET / CT.

9. 9mCi (333MBq) 18 The method of any one of claims 1 to 8, wherein F-DCFPyL is administered to the subject by IV injection.

10. The method of any one of claims 1 to 9, further comprising treating the subject based on said determination.

11. 10. The method of claim 9, wherein the treatment is any one of the treatments provided herein.

12. The method of any one of claims 1 to 11, wherein making a treatment management decision comprises any one or more of the treatment management decisions provided herein.

13. The method according to any one of claims 1 to 12, wherein the subject is any one of the subjects as described herein.

14. The method of any one of claims 1 to 13, wherein the subject has undergone a prior diagnostic test, such as a PSA test or a conventional imaging test.

15. 14. The method of claim 13, wherein the prior diagnostic test was a negative or equivocal finding for prostate cancer in a conventional imaging test.

16. The method of any one of claims 1 to 15, further comprising the step of performing an additional diagnostic test on the subject, such as a PSA test or a conventional imaging test.

17. 17. The method of claim 16, wherein the PSA test result was a detectable or rising PSA following radical prostatectomy in the subject.

18. 16. The method of claim 15, wherein the PSA test result was an increase in PSA levels in the subject after radiation therapy, cryotherapy, or brachytherapy.

Citation Information

Patent Citations

  • Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications

    WO2018081354A1